Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)Completed
NCT00666016Phase 2Updated Dec 18, 2025
Sponsor: Hoffmann-La Roche
Non-Alcoholic Steatohepatitis (NASH)
France
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid TumorsCompleted
NCT05240898Phase 1Updated Dec 18, 2025
Sponsor: Hoffmann-La Roche
Advanced Solid Tumors
United States
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced CancerCompleted
NCT05846594NAUpdated Dec 17, 2025
Sponsor: Hoffmann-La Roche
Metastatic Lung Cancer · Metastatic Gastrointestinal Cancer
France, Germany, Italy, Spain
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic SyndromeActive Not Recruiting
NCT05627557Phase 3Updated Dec 15, 2025
Sponsor: Hoffmann-La Roche
Childhood Idiopathic Nephrotic Syndrome
United States, Belgium, Brazil, China, France +4 more
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCCCompleted
NCT04862949N/AUpdated Dec 12, 2025
Sponsor: CHA University
Advanced Hepatocellular Carcinoma
South Korea
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.Recruiting
NCT06280755N/AUpdated Dec 12, 2025
Sponsor: icometrix
Multiple Sclerosis · NMO Spectrum Disorder · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease · Radiologically Isolated Syndrome
Czechia, Germany
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaCompleted
NCT05908786Phase 1, Phase 2Updated Dec 11, 2025
Sponsor: Hoffmann-La Roche
Carcinoma, Hepatocellular
United States, Austria, France, Germany, New Zealand +4 more
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung CancerCompleted
NCT05171777Phase 2Updated Dec 11, 2025
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer
United States, Argentina, Brazil, Canada, Chile +7 more
Biomechanical Precision Medicine Registry for Patients With and Without Heart FailureRecruiting
NCT03480633N/AUpdated Dec 9, 2025
Sponsor: Massachusetts General Hospital
Heart Failure With Normal Ejection Fraction · Heart Failure With Reduced Ejection Fraction · Heart Failure, Right Sided · Heart Failure With Mid Range Ejection Fraction
United States
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.Recruiting
NCT06733038Phase 3Updated Dec 8, 2025
Sponsor: Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
Italy
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerCompleted
NCT03735121Phase 3Updated Dec 5, 2025
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
Argentina, Brazil, Chile, China, Costa Rica +18 more
Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive Not Recruiting
NCT03620903Phase 2Updated Dec 5, 2025
Sponsor: Christian Buske
Waldenstrom Macroglobulinemia
Germany, Greece
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.Completed
NCT05630066Phase 2Updated Dec 4, 2025
Sponsor: Hoffmann-La Roche
Angelman Syndrome
United States, Australia, France, Germany, Italy +1 more
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruiting
NCT05786716Phase 2, Phase 3Updated Dec 2, 2025
Sponsor: Cancer Research UK
Haematological Malignancy · Colorectal Neoplasms · Urinary Bladder Neoplasm · Gallbladder Neoplasms
United Kingdom
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaCompleted
NCT05364424Phase 1Updated Dec 1, 2025
Sponsor: Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma (DLBCL)
United States
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminated
NCT05180006Phase 2Updated Dec 1, 2025
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer
France
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes MellitusCompleted
NCT05814107Phase 1Updated Nov 28, 2025
Sponsor: Carmot Australia First Pty Ltd
Type 2 Diabetes · Overweight or Obesity
Australia, Mexico
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerCompleted
NCT01358877Phase 3Updated Nov 28, 2025
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Austria, Belgium +37 more
Phase II Trial GA101 Inbrutinib B CLLCompleted
NCT02666898Phase 2Updated Nov 26, 2025
Sponsor: French Innovative Leukemia Organisation
Leukemia, Lymphocytic, Chronic, B-Cell
France
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerActive Not Recruiting
NCT01898117Phase 2Updated Nov 26, 2025
Sponsor: The Netherlands Cancer Institute
Breast Cancer
Netherlands
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous MeningitisCompleted
NCT01373710Phase 1, Phase 2Updated Nov 24, 2025
Sponsor: Institut Curie
Metastatic Breast Cancer · Carcinomatous Meningitis
France
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Recruiting
NCT05768178Phase 2, Phase 3Updated Nov 24, 2025
Sponsor: Cancer Research UK
Haematological Malignancy · Melanoma · Thyroid Cancer, Papillary · Ovarian Neoplasms
United Kingdom
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionRecruiting
NCT05770102Phase 2, Phase 3Updated Nov 24, 2025
Sponsor: Cancer Research UK
Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type
United Kingdom
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFRecruiting
NCT04702256Phase 3Updated Nov 24, 2025
Sponsor: Assistance Publique - Hôpitaux de Paris
Lupus Nephritis · Systemic Lupus Erythematosus (SLE)
France
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.Recruiting
NCT05770544Phase 2, Phase 3Updated Nov 24, 2025
Sponsor: Cancer Research UK
Haematological Malignancy · Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders
United Kingdom

Previous page Next page